By using a change-as-you-go strategy that evolves as new data emerges, this adaptive design can save time, money and resources. But how can you get there?
September 30, 2020
- Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
- Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
- The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know
- Flow Cytometry User Groups And The Relaunch Of The NWFCS
- Live Dead Measurement and Cell Viability
Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...
Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...
The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know
Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
